Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
prednisone + valacyclovir
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of prednisone (a corticosteroid) and valacyclovir (an antiviral). Prednisone works by controlling inflammation and modulating immune system responses, while valacyclovir is converted to acyclovir in the body and stops the growth of herpes viruses. This combination is primarily used for treating Bell's palsy and herpes zoster (shingles), with studies showing significantly better outcomes compared to no treatment or single-drug approaches.
- Brand names
- Valtrex
- Other names
- prednisone + valacyclovirprednisolone + valacyclovir
02
Targets
GR (Glucocorticoid receptor)Herpesvirus DNA polymerase
Beyond the preview
Go deeper on prednisone + valacyclovir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on prednisone + valacyclovir.